Skip to content

Study · Systematic review · 2020

6 results

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.

Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E

Annals of internal medicine30 Jun 2020Cited by 283 (Europe PMC)

PMID32598218 (opens in a new tab)DOI10.7326/m20-0864 (opens in a new tab)PepBankPUB-32598218
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes at increased cardiovascular risk on metformin-based background treatment, liraglutide reduced all-cause mortality.

    In plain wordsIn people with type 2 diabetes and higher heart risk who took metformin, liraglutide lowered the risk of death from any cause.

    Peptide
    Liraglutide
    Outcome
    DecreaseAll-cause mortality
    Study

    n: not reported in source

    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In patients at increased cardiovascular risk receiving metformin-based background treatment (21 trials), oral semaglutide, empagliflozin, liraglutide, extended-release exenatide, and dapagliflozin reduced all-cause mortality.
    2 context sentences
    Summary · context
    To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes.
    Summary · context
    453 trials assessing 21 antidiabetic interventions from 9 drug classes were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes at increased cardiovascular risk on metformin-based background treatment, oral semaglutide reduced all-cause mortality.

    In plain wordsIn people with type 2 diabetes and higher heart risk who took metformin, oral semaglutide lowered the risk of death from any cause.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause mortality
    Study

    n: not reported in source

    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    In patients at increased cardiovascular risk receiving metformin-based background treatment (21 trials), oral semaglutide, empagliflozin, liraglutide, extended-release exenatide, and dapagliflozin reduced all-cause mortality.
    2 context sentences
    Summary · context
    To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes.
    Summary · context
    453 trials assessing 21 antidiabetic interventions from 9 drug classes were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes at increased cardiovascular risk on metformin-based background treatment, liraglutide reduced cardiovascular death.

    In plain wordsIn people with type 2 diabetes and higher heart risk who took metformin, liraglutide lowered the risk of heart-related death.

    Peptide
    Liraglutide
    Outcome
    DecreaseCardiovascular death
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascular death.
    2 context sentences
    Summary · context
    To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes.
    Summary · context
    453 trials assessing 21 antidiabetic interventions from 9 drug classes were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes at increased cardiovascular risk on metformin-based background treatment, oral semaglutide reduced cardiovascular death.

    In plain wordsIn people with type 2 diabetes and higher heart risk who took metformin, oral semaglutide lowered the risk of heart-related death.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular death
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascular death.
    2 context sentences
    Summary · context
    To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes.
    Summary · context
    453 trials assessing 21 antidiabetic interventions from 9 drug classes were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide was linked with lower odds of stroke.

    In plain wordsIn adults with type 2 diabetes, subcutaneous semaglutide was linked with lower odds of stroke.

    Peptide
    Semaglutide
    Outcome
    DecreaseStroke
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Odds of stroke were lower with subcutaneous semaglutide and dulaglutide.
    2 context sentences
    Summary · context
    To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes.
    Summary · context
    453 trials assessing 21 antidiabetic interventions from 9 drug classes were included.
  6. 06HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, subcutaneous semaglutide increased diabetic retinopathy.

    In plain wordsIn adults with type 2 diabetes, subcutaneous semaglutide was linked with more diabetic retinopathy.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiabetic retinopathy
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous semaglutide and canagliflozin increased diabetic retinopathy
    2 context sentences
    Summary · context
    To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes.
    Summary · context
    453 trials assessing 21 antidiabetic interventions from 9 drug classes were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.